Immunology

Edited by: Eugene Russo T CELL STARTER: Harvard's Michael Grusby believes that research on Stat pathways will lead to a better understanding of T cell differentiation. M.H. Kaplan, U. Schindler, S.T. Smiley, M.J. Grusby, "Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells," Immunity, 4:313-9, 1996. (Cited in more than 75 publications as of February 1998) Comments by Michael J. Grusby, Department of Immunology and Infectious Diseases, Harvard School of Public

Written byEugene Russo
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Edited by: Eugene Russo


T CELL STARTER: Harvard's Michael Grusby believes that research on Stat pathways will lead to a better understanding of T cell differentiation.
M.H. Kaplan, U. Schindler, S.T. Smiley, M.J. Grusby, "Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells," Immunity, 4:313-9, 1996. (Cited in more than 75 publications as of February 1998)

Comments by Michael J. Grusby, Department of Immunology and Infectious Diseases, Harvard School of Public Health

Sometimes good cells turn bad. When produced at the wrong time, T helper cells, which are meant to fight off harmful antigens, can end up attacking the molecules, cells, and tissues that they're suppose to be defending, thereby causing autoimmune diseases. Potential therapies for such disorders may entail the manipulation of the cell pathways that lead to T helper cell differentiation. Scientists have attempted to do so by identifying the molecules involved ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies